American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
American Journal of Medical Case Reports. 2019, 7(12), 337-341
DOI: 10.12691/ajmcr-7-12-9
Open AccessArticle

Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review

Pramod Theetha Kariyanna1, Syed Haseeb1, Yuvraj Singh Chowdhury1, Apoorva Jayarangaiah2, Andrii Maryniak1, George Mo1, Sudhanva Hegde1, Jonathan D. Marmur1 and Isabel. M. McFarlane1,

1Division of Cardiovascular Disease and Department of Internal Medicine, State University of New York: Downstate Medical Center, Brooklyn, New York, United States-11203.

2Department of Internal Medicine, NYC Health and Hospitals/Jacobi Medical Center, Bronx, N.Y., U.S.A-10461

Pub. Date: October 18, 2019

Cite this paper:
Pramod Theetha Kariyanna, Syed Haseeb, Yuvraj Singh Chowdhury, Apoorva Jayarangaiah, Andrii Maryniak, George Mo, Sudhanva Hegde, Jonathan D. Marmur and Isabel. M. McFarlane. Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review. American Journal of Medical Case Reports. 2019; 7(12):337-341. doi: 10.12691/ajmcr-7-12-9


Ever since evidence about the increased risk of stent thrombosis with drug eluting stents (DES) surfaced in 2005, the Food and Drug Administration (FDA) has recommended the use of dual antiplatelet therapy (aspirin with P2Y12 inhibitor) following DES placement. The PLATO trial demonstrated lower mortality rates with the use of Ticagrelor when compared to clopidogrel (9.8% vs. 11.7%, p<0.001) when treating patients with acute coronary syndrome. Given their pleiotropic benefits, statins are today the second most prescribed drug in the United States and often co-prescribed with Ticagrelor. FDA’s post market surveillance of Ticagrelor use along with statins in post-myocardial infarction care is now revealing novel and serious adverse events. We present two cases of rhabdomyolysis and acute renal failure (ARF) which develop while the patients were on statins and Ticagrelor. Case 1: A 66-year-old female presented with bilateral thigh pain for 3 days. One month prior to presentation, she was managed for non-ST segment elevation myocardial infarction (NSTEMI) and had been started on aspirin, ticagrelor and simvastatin. Laboratory values revealed creatinine kinase (CK) level at 40,000 U/L and creatinine 3.2 mg/dL suggesting rhabdomyolysis and ARF. Case 2: A 63-year-old male presented with generalized body aches and fatigue for 4 days. He had sustained STEMI two months before and received two drug eluting stents (DES) and aspirin, ticagrelor and rosuvastatin had been initiated. CK was 380,000 U/L and creatinine 7.94 mg/dL suggesting rhabdomyolysis and ARF. Both patients presented with rhabdomyolysis and acute renal failure within weeks after ticagrelor and statin were commenced. A review of the literature indicated that 11 similar cases of ticagrelor-induced ARF and rhabdomyolysis had been reported. Ticagrelor competes with statins when metabolized by cytochrome P450 (CYP) 3A4 leading to statin retention, leading to major adverse effects like rhabdomyolysis and acute renal failure. Our review is intended to alert clinicians about this important drug interaction.

ticagrelor statins rhabdomyolysis acute renal failure drug interaction cytochrome P450 (CYP) 3A4 adenosine diphosphate (ADP) receptor P2Y12

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomized placebo-controlled trial. The Lancet. 2005 Nov 5; 366(9497): 1607-21.
[2]  CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial) Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine. 2001 Aug 16; 345(7): 494-502.
[3]  ames SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial, Br Med J , 2011, vol. 342 d3527.
[4]  Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2014 Oct 1; 34(10): 1077-90.
[5]  Danielak D, Karaźniewicz-Łada M, Główka F. Ticagrelor in modern cardiology-an up-to-date review of most important aspects of ticagrelor pharmacotherapy. Expert opinion on pharmacotherapy. 2018 Jan 22; 19(2): 103-12.
[6]  Stanley M, Adigun R. Rhabdomyolysis. InStatPearls [Internet] 2017 Oct 9. StatPearls Publishing.
[7]  Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J. 2004;147(6): 956-65.
[8]  Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacotherapy. 2002; 36: 288-95.
[9]  Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011; 39: 703-10.
[10]  Hoffman KB, Kraus C, Dimbil M, Golomb BA. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PloS one. 2012 Aug 22; 7(8): e42866.
[11]  Asheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. Journal of the American College of Cardiology. 2007 Jul 31; 50(5): 409-18.
[12]  Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. Jama. 2003 Apr 2; 289(13): 1681-90.
[13]  Milicić D. ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome. Acta medica Croatica: casopis Hravatske akademije medicinskih znanosti. 2004; 58(2): 129-34.
[14]  Nicolantonio JJ, Serebruany VL. Angiotensin Receptor Blockers Worsen Renal Function and Dyspnea on Ticagrelor: A Potential Ticagrelor-Angiotensin Receptor Blocker Interaction?. Clinical cardiology. 2012 Nov; 35(11): 647-8.
[15]  Kido K, Wheeler MB, Seratnahaei A, Bailey A, Bain JA. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. Journal of the American Pharmacists Association. 2015 May 1; 55(3): 320-3.
[16]  Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. The American journal of case reports. 2017; 18: 1238.
[17]  Samuel G, Atanda AC, Onyemeh A, Awan A, Ajiboye O. A Unique Case of Drug Interaction between Ticagrelor and Statin Leading to Acute Renal Failure. Cureus. 2017 Aug; 9(8).
[18]  Banakh I, Haji K, Kung R, Gupta S, Tiruvoipati R. Severe rhabdomyolysis due to presumed drug interactions between atorvastatin with amlodipine and ticagrelor. Case reports in critical care. 2017; 2017.
[19]  YILMAZ B, YILMAZ A, ERSAN S, Alper AL, GÜLLE S. Tikagrelor Kullanımı Atorvastatin İlişkili Rabdomiyoliz Riskini Artırabilir Ticagrelor Use may Increase the Risk of Atorvastatin-Related Rhabdomyolysis.
[20]  New J, Le K, Wong KA, Choi SJ, Danh CL, et al. (2017). A Case of Acute Renal Failure and Rhabdomyolysis associated with the Concomitant Use of Ticagrelor, Rosuvastatin, and Losartan. JSM Intern Med 2(1): 1004.
[21]  Park IS, Lee SB, Song SH, Seong EY, Kim IY, Rhee H, Kim MJ, Lee DW. Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis. Anatolian journal of cardiology. 2018 Mar; 19(3): 225.
[22]  Kirhmajer MV, Šarinić VM, Šimičević L, Ladić I, Putarek K, Banfić L, Božina N. Rosuvastatin‐induced rhabdomyolysis–Possible role of ticagrelor and patients’ Pharmacogenetic profile. Basic & clinical pharmacology & toxicology. 2018 May 7.
[23]  Danielak, D., et al. (2018). “Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins.” Drugs 78(11): 1105-1112.
[24]  Poon, S. H. and L. Stoddart (2017). “Unexpected Cause of Rhabdomyolysis and Proximal Muscle Weakness.” Arthritis Care Res (Hoboken) 69(10): 1599-1605.
[25]  Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec; 19(6):403-14.
[26]  Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012 May-Jun; 6(3):208-15.
[27]  Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD. Effect of statins on skeletal muscle function. Circulation. 2013 Jan 1; 127(1): 96-103.
[28]  Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to Statins: Mechanisms and Management. Diabetes Care. 2013 Aug;36(Suppl 2): S325-S330.
[29]  Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015; 11(1): 1-23.
[30]  Muntean DM, Thompson PD, Catapano AL, Stasiolek M, Fabis J, Muntner P, Serban MC, Banach M. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today. 2017 Jan; 22(1): 85-96.
[31]  Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ ADA/ AGS/ APhA/ ASPC/ NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun; 73(24): 3168-3209.
[32]  Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, Pope J, Tashakkor AY. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016 Jul; 32(7 Suppl):S35-65.
[33]  Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 1; 36(17): 1012-22.
[34]  Saxon DR, Eckel RH. Statin Intolerance: A Literature Review and Management Strategies. Prog Cardiovasc Dis. 2016 Sep-Oct; 59(2): 153-164.